Abstract 4507: New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients
Viviana Guadagnuolo(University of Bologna), Giovanni Martinelli(University of Bologna), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Chiara Sartor(University of Bologna), Maria Chiara Fontana(Istituto Oncologico Romagnolo), Emanuela Ottaviani(University of Bologna), Mariachiara Abbenante(University of Bologna), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Sarah Parisi(University of Bologna), Cristina Papayannidis(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Marco Manfrini(University of Padua), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonella Padella(University of Bologna), Giovanni Marconi(University of Bologna), Anna Ferrari(University of Bologna)
Cited by 0
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644